Wednesday, June 17, 2026
🇺🇸 FDA

pharma · Migraine · Narcolepsy

H. Lundbeck A/S

H. Lundbeck A/S clinical programs — 17 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Postboks 361, LYSAKER, Bærum 1326, NO, Valby, CN HQ
112 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Postboks 361, LYSAKER, Bærum 1326, NO, Valby, CN
Employees
112
Programs
17
Drugs
14
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

H. Lundbeck A/S projects

17 ClinicalTrials.gov programs sponsored by H. Lundbeck A/S.

H. Lundbeck A/S has 17 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

17 programs

Clinical programs

  1. 19356A

    H. Lundbeck A/S

    Migraine

    phase 3 small molecule active

    1 trial

  2. 20432A

    H. Lundbeck A/S

    Multiple System Atrophy

    phase 3 small molecule active

    1 trial

  3. Bifeprunox

    H. Lundbeck A/S

    Schizophrenia

    phase 3 small molecule terminated

    1 trial

  4. Eptinezumab

    H. Lundbeck A/S

    Migraine

    phase 3 small molecule completed

    1 trial

  5. Lu AF35700

    H. Lundbeck A/S

    Treatment-resistant Schizophrenia

    phase 3 small molecule terminated

    1 trial

  6. VYEPTI 100 mg concentrate for solution for infusion

    H. Lundbeck A/S

    Chronic migraine

    phase 3 small molecule active

    1 trial

  7. VYEPTI 100 mg concentrate for solution for infusion

    H. Lundbeck A/S

    Migraine

    phase 3 small molecule active

    1 trial

  8. 20433A

    H. Lundbeck A/S

    Cushing's Disease

    phase 2 other active

    1 trial

  9. Lu AA34893

    H. Lundbeck A/S

    Depression in Patients With Bipolar Disorder

    phase 2 small molecule terminated

    1 trial

  10. Lu AE58054

    H. Lundbeck A/S

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  11. Placebo to match IMP Lu AG09222

    H. Lundbeck A/S

    Migraine

    phase 2 small molecule active

    1 trial

  12. 20453A

    H. Lundbeck A/S

    Active, moderate-to-severe TED

    phase 1 other active

    1 trial

  13. 20653A

    H. Lundbeck A/S

    Narcolepsy

    phase 1 other active

    1 trial

  14. 21117A

    H. Lundbeck A/S

    Narcolepsy

    phase 1 other active

    1 trial

  15. Lu AF28996

    H. Lundbeck A/S

    Parkinson Disease

    phase 1 small molecule active

    1 trial

  16. Lu AF28996 in Patients With Parkinson's Disease

    H. Lundbeck A/S

    Parkinson's Disease

    phase 1 other active

    1 trial

  17. VYEPTI 100 mg concentrate for solution for infusion

    H. Lundbeck A/S

    Chronic Migrane, Migrane, Medication Overuse Headache

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does H. Lundbeck A/S have?

17 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.